Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.73 |
| ▸ | USP2 | O75604 | 3/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.73 |
| ▸ | RECQL | P46063 | 2/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
| ▸ | EGFR | P00533 | 1/20 | 0.73 |
| ▸ | LCK | P06239 | 1/20 | 0.73 |
| ▸ | FYN | P06241 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | HTR2A | P28223 | 1/20 | 0.73 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.73 |
| ▸ | CA2 | P00918 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 3/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157442 | 1.00 | SLC7A5 (0.73) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| SCHEMBL29405778 | 1.00 | SLC7A5 (0.73) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| SCHEMBL28512 | 1.00 | SLC7A5 (0.73) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Hydrochloric Acid SCHEMBL7042725 | 0.98 | SLC7A5 (0.71) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Hydrochloric Acid SCHEMBL7042729 | 0.98 | SLC7A5 (0.71) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| SCHEMBL9506322 | 0.91 | SLC7A5 (0.61) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| SCHEMBL25578547 | 0.87 | ALOX15 (0.54) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| SCHEMBL29478421 | 0.86 | SLC7A5 (0.62) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| SCHEMBL43915 | 0.86 | SLC7A5 (0.62) | SLC7A5USP2PTGS1KDM4EALOX15 | |
| Levodopa SCHEMBL29868926 | 0.86 | SLC7A5 (0.96) | SLC7A5USP2PTGS1KDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11931329-B2 | Compositions and methods for treating anxiety-related disorders | YAMO PHARMACEUTICALS LLC (US) | 2024-03-19 | — | — | US | claimed |
| US-20240024268-A1 | Methods for Dopamine Modulation in Human Neurologic Diseases | SACKNER BERNSTEIN JONATHAN (US) | 2024-01-25 | — | — | US | claimed |
| US-20240016815-A1 | COMPOSITIONS AND METHODS FOR MODULATING CANCER IN NON-HUMAN MAMMALS | HOFFMAN TECHNOLOGIES LLC | 2024-01-18 | — | — | US | claimed |
| US-11806326-B2 | Methods for dopamine modulation in human neurologic diseases | SACKNER BERNSTEIN JONATHAN (US) | 2023-11-07 | — | — | US | claimed |
| US-20230331779-A1 | BISPECIFIC FUSION POLYPEPTIDE COMPOUND | SHAANXI MICOT TECHNOLOGY CO., LTD. (CN) | 2023-10-19 | — | — | US | claimed |
| US-11786496-B2 | Composition and methods for treating intestinal hyperpermeability | YAMO PHARMACEUTICALS LLC (US) | 2023-10-17 | — | — | US | claimed |
| EP-4212542-A1 | BISPECIFIC FUSION POLYPEPTIDE COMPOUND | Shaanxi Micot Technology Limited Company (CN) | 2023-07-19 | — | — | EP | claimed |
| US-20230141609-A1 | Methods of Treating Amyotrophic Lateral Sclerosis and Symptoms | YAMO PHARMACEUTICALS LLC (US) | 2023-05-11 | — | — | US | claimed |
| US-20230040681-A1 | COMPOSITIONS AND METHODS FOR TREATING ANXIETY-RELATED DISORDERS | YAMO PHARMACEUTICALS LLC (US) | 2023-02-09 | — | — | US | claimed |
| US-11534420-B2 | Compositions and methods for treating cancer | TYME, INC. (US) | 2022-12-27 | — | — | US | claimed |
| WO-2015061328-A2 | COMPOSITIONS AND METHODS FOR TREATING INTESTINAL HYPERPERMEABILITY | HOFFMAN STEVEN (US) | 2015-04-30 | — | — | WO | claimed |
| WO-2015061288-A1 | TYROSINE DERIVATIVES AND COMPOSITIONS COMPRISING THEM | TYME, INC. (US) | 2015-04-30 | — | — | WO | claimed |
| US-20150112116-A1 | TYROSINE DERIVATIVES AND COMPOSITIONS COMPRISING THEM | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-04-23 | — | — | US | claimed |
| US-20150110735-A1 | HIGH-SPEED CENTRIFUGAL MIXING DEVICES AND METHODS OF USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-04-23 | — | — | US | claimed |
| US-20150111878-A1 | COMPOSITIONS AND METHODS FOR TREATING INTESTINAL HYPERPERMEABILITY | HOFFMAN STEVEN (US) | 2015-04-23 | — | — | US | claimed |
| US-20150111937-A1 | Compositions and Methods for Treating Intestinal Hyperpermeability | YAMO PHARMACEUTICALS LLC | 2015-04-23 | — | — | US | claimed |
| EP-2804599-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | Tyme, Inc. (US) | 2014-11-26 | — | — | EP | claimed |
| WO-2013109610-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | HOFFMAN STEVEN (US) | 2013-07-25 | — | — | WO | claimed |
| US-20130184214-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2013-07-18 | — | — | US | claimed |
| US-8481498-B1 | Pharmaceutical compositions and methods | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2013-07-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331779-A1 | BISPECIFIC FUSION POLYPEPTIDE COMPOUND | CALCR, BID, CASR | SLC7A5 2981/4885USP2 2151/4885PTGS1 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.